269 related articles for article (PubMed ID: 31033566)
1. New therapeutic agents in gastrointestinal stromal tumours.
Falkenhorst J; Hamacher R; Bauer S
Curr Opin Oncol; 2019 Jul; 31(4):322-328. PubMed ID: 31033566
[TBL] [Abstract][Full Text] [Related]
2. [Advanced GIST: Which treatments in 2022?].
Mas L; Bachet JB
Bull Cancer; 2022 Oct; 109(10):1082-1087. PubMed ID: 35934543
[TBL] [Abstract][Full Text] [Related]
3. New drugs in gastrointestinal stromal tumors.
Martin-Broto J; Moura DS
Curr Opin Oncol; 2020 Jul; 32(4):314-320. PubMed ID: 32541319
[TBL] [Abstract][Full Text] [Related]
4. New Tyrosine Kinase Inhibitors for the Treatment of Gastrointestinal Stromal Tumors.
Serrano C; Bauer S
Curr Oncol Rep; 2022 Feb; 24(2):151-159. PubMed ID: 35061196
[TBL] [Abstract][Full Text] [Related]
5. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
Kang YK; George S; Jones RL; Rutkowski P; Shen L; Mir O; Patel S; Zhou Y; von Mehren M; Hohenberger P; Villalobos V; Brahmi M; Tap WD; Trent J; Pantaleo MA; Schöffski P; He K; Hew P; Newberry K; Roche M; Heinrich MC; Bauer S
J Clin Oncol; 2021 Oct; 39(28):3128-3139. PubMed ID: 34343033
[TBL] [Abstract][Full Text] [Related]
6. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
Heinrich MC; Jones RL; von Mehren M; Schöffski P; Serrano C; Kang YK; Cassier PA; Mir O; Eskens F; Tap WD; Rutkowski P; Chawla SP; Trent J; Tugnait M; Evans EK; Lauz T; Zhou T; Roche M; Wolf BB; Bauer S; George S
Lancet Oncol; 2020 Jul; 21(7):935-946. PubMed ID: 32615108
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal stromal tumor: a review of current and emerging therapies.
Al-Share B; Alloghbi A; Al Hallak MN; Uddin H; Azmi A; Mohammad RM; Kim SH; Shields AF; Philip PA
Cancer Metastasis Rev; 2021 Jun; 40(2):625-641. PubMed ID: 33876372
[TBL] [Abstract][Full Text] [Related]
8. New treatments in advanced gastrointestinal stromal tumor.
Serrano C
Curr Opin Oncol; 2021 Jul; 33(4):323-328. PubMed ID: 33867479
[TBL] [Abstract][Full Text] [Related]
9. Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors.
Smrke A; Gennatas S; Huang P; Jones RL
Future Oncol; 2020 Aug; 16(22):1639-1646. PubMed ID: 32517495
[TBL] [Abstract][Full Text] [Related]
10. [Gastrointestinal stromal tumors (GIST)].
Jaros D; Bozic B; Sebesta C
Wien Med Wochenschr; 2023 Jun; 173(9-10):201-205. PubMed ID: 36155864
[TBL] [Abstract][Full Text] [Related]
11. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.
Jones RL; Serrano C; von Mehren M; George S; Heinrich MC; Kang YK; Schöffski P; Cassier PA; Mir O; Chawla SP; Eskens FALM; Rutkowski P; Tap WD; Zhou T; Roche M; Bauer S
Eur J Cancer; 2021 Mar; 145():132-142. PubMed ID: 33465704
[TBL] [Abstract][Full Text] [Related]
12. Proteogenomics for the Study of Gastrointestinal Stromal Tumors.
Kondo T
Adv Exp Med Biol; 2016; 926():139-151. PubMed ID: 27686810
[TBL] [Abstract][Full Text] [Related]
13. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
Janku F; Abdul Razak AR; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Somaiah N; Hu S; Rosen O; Su Y; Ruiz-Soto R; Gordon M; George S
J Clin Oncol; 2020 Oct; 38(28):3294-3303. PubMed ID: 32804590
[TBL] [Abstract][Full Text] [Related]
14. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
15. An updated review of the treatment landscape for advanced gastrointestinal stromal tumors.
Patel SR; Reichardt P
Cancer; 2021 Jul; 127(13):2187-2195. PubMed ID: 33974733
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
Mohammadi M; Gelderblom H
Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
[No Abstract] [Full Text] [Related]
17. Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis.
Ravegnini G; Nannini M; Sammarini G; Astolfi A; Biasco G; Pantaleo MA; Hrelia P; Angelini S
Int J Mol Sci; 2015 Jul; 16(7):15592-608. PubMed ID: 26184165
[TBL] [Abstract][Full Text] [Related]
18. Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor.
Kang G; Bae BN; Sohn BS; Pyo JS; Kang GH; Kim KM
Target Oncol; 2015 Dec; 10(4):597-601. PubMed ID: 25735500
[TBL] [Abstract][Full Text] [Related]
19. Translational insights into gastrointestinal stromal tumor and current clinical advances.
Hemming ML; Heinrich MC; Bauer S; George S
Ann Oncol; 2018 Oct; 29(10):2037-2045. PubMed ID: 30101284
[TBL] [Abstract][Full Text] [Related]
20. Intrigue: Phase III study of ripretinib versus sunitinib in advanced gastrointestinal stromal tumor after imatinib.
Nemunaitis J; Bauer S; Blay JY; Choucair K; Gelderblom H; George S; Schöffski P; Mehren MV; Zalcberg J; Achour H; Ruiz-Soto R; Heinrich MC
Future Oncol; 2020 Jan; 16(1):4251-4264. PubMed ID: 31755321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
